secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001159036-24-000043
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme beats Q2 with $231M revenue, $0.91 non-GAAP EPS; reiterates raised 2024 outlook
--------------------------------------------------------------------------------

- Revenue $231M (+5% YoY), net income $93M (+24%), GAAP EPS $0.72, non-GAAP EPS $0.91.
- Royalty revenue $124.9M (+12% YoY) led by Phesgo, VYVGART Hytrulo, and Teriparatide launches.
- Reiterated FY2024 guidance: rev $935-1015M, adj EBITDA $555-615M, non-GAAP EPS $3.65-4.05.
- Partner approvals: Ocrevus SC (EU/UK), VYVGART Hytrulo for CIDP (US); BMS nivolumab SC PDUFA Dec 29, 2024.
- Completed $250M ASR (6.5M shares at $38.35); new EU patent extends ENHANZE royalty through March 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903624000043/0001159036-24-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903624000043/halo-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001159036-24-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer